Guobang Pharma Ltd Asset Resilience Ratio
Guobang Pharma Ltd asset resilience ratio. Guobang Pharma Ltd (605507) has an Asset Resilience Ratio of 9.44% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 605507 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Guobang Pharma Ltd (2019–2025)
Asset resilience ratio of Guobang Pharma Ltd from 2019 to 2025. This chart shows how Guobang Pharma Ltd's Asset Resilience Ratio has changed over time. Read Guobang Pharma Ltd (605507) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Guobang Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Guobang Pharma Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.08 Billion | 9.44% |
| Total Liquid Assets | CN¥1.08 Billion | 9.44% |
Asset Resilience Insights
- Limited Liquidity: Guobang Pharma Ltd maintains only 9.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guobang Pharma Ltd Industry Peers by Asset Resilience Ratio
Compare Guobang Pharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Guobang Pharma Ltd Asset Resilience Ratio by Year (2019–2025)
Guobang Pharma Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Guobang Pharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.32% | CN¥1.24 Billion ≈ $181.88 Million |
CN¥10.98 Billion ≈ $1.61 Billion |
+5.59pp |
| 2024-12-31 | 5.73% | CN¥617.66 Million ≈ $90.38 Million |
CN¥10.78 Billion ≈ $1.58 Billion |
+1.23pp |
| 2023-12-31 | 4.50% | CN¥465.99 Million ≈ $68.19 Million |
CN¥10.36 Billion ≈ $1.52 Billion |
-4.62pp |
| 2022-12-31 | 9.12% | CN¥824.56 Million ≈ $120.66 Million |
CN¥9.04 Billion ≈ $1.32 Billion |
-7.63pp |
| 2021-12-31 | 16.75% | CN¥1.26 Billion ≈ $184.12 Million |
CN¥7.51 Billion ≈ $1.10 Billion |
+16.75pp |
| 2020-12-31 | 0.00% | CN¥34.78K ≈ $5.09K |
CN¥5.51 Billion ≈ $806.08 Million |
-3.15pp |
| 2019-12-31 | 3.15% | CN¥149.87 Million ≈ $21.93 Million |
CN¥4.76 Billion ≈ $696.45 Million |
-- |
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more